Document is current
Any future updates will be listed below
-
Authors
Yang-Schulz, Annie
Zacharopoulou, Maria
Yilmaz, Sema Zeynep
Banerjee, Anupam
Saha, Satyaki
Nietlispach, Daniel
Ohlmeyer, Michael
Gur, Mert
Itzhaki, Laura S.
Bahar, Ivet
Gordon, Reuven
-
Funding
Funding for this research was provided by:
Human Frontier Science Program (RGP0027/2020, RGP0027/2020, RGP0027/2020, RGP0027/2020, RGP0027/2020, RGP0027/2020, RGP0027/2020)
Biotechnology and Biological Sciences Research Council (BB/T002697/1, BB/T002697/1)
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 28 November 2024
First Online: 16 January 2025
Competing interests
: M.O. is inventor or co-inventor of the tricyclic sulfonamides ("SMAP"), including ATUX-8385, see US Patent 10,759,790. All other authors declare no competing interests.
